Browse the evidence

No changes were observed in any variable in the control group.

Regular activity without resistance training does not lead to changes in arterial stiffness or left ventricular mass.

Federal and corporate policies have contributed to an unhealthy environment.

Awareness of policy impacts can guide healthier choices and advocacy.

Prolonged calorie restriction has been shown to extend both the median and maximal lifespan in a variety of lower species.

Calorie restriction may be a viable strategy for extending lifespan, though this is primarily observed in non-human species.

Recent clinical trials have not observed significant effects of n-3 PUFA supplementation on cardiovascular disease (CVD) events.

This suggests that n-3 PUFA supplementation may not be effective for CVD prevention in recent studies.

Perioperative adverse events of metabolic surgery are similar to other gastrointestinal surgeries.

Surgeons and patients can expect a safety profile for metabolic surgery that is consistent with other gastrointestinal procedures.

Identifying components of neuroendocrine systems is important for developing obesity therapies.

Research should focus on neuroendocrine components to inform obesity treatment strategies.

No significant differences were noted in body composition components between groups.

Training volume may not significantly affect body composition in the early stages of resistance training.

Cardiovascular disease (CVD) is the leading cause of death and disability worldwide.

Healthcare practitioners should prioritize addressing CVD in their practice.

Dapagliflozin is a selective SGLT2 inhibitor approved to improve glycemic control in adults with type 2 diabetes.

Dapagliflozin can be considered as a treatment option for managing blood sugar levels in adults with type 2 diabetes.

There is no consensus definition for 'failure' in resistance training literature.

Practitioners should be aware of the lack of standardization in training definitions when interpreting research.

There was no significant change in telomere length at 6 months.

Weight loss interventions may not affect telomere length in the short term.

Gestational diabetes mellitus (GDM) recurrence affects 40 to 73% of women.

Healthcare providers should be aware of the high recurrence rate of GDM in women.

Reduced microbial diversity in the gut is implicated in several gastrointestinal diseases and cancers.

Maintaining gut microbiome diversity may be crucial for preventing gastrointestinal diseases.

There is a need for the development of safe and efficacious drug treatments for obesity.

There is an opportunity for researchers and pharmaceutical companies to explore new obesity treatments.

The latest randomized clinical trial on pramlintide/metreleptin was stopped due to safety concerns.

Practitioners should be cautious about the use of pramlintide/metreleptin until safety concerns are addressed.

Preoperative use of GLP-1 receptor agonists is not significantly associated with the odds of postoperative aspiration pneumonia.

Clinicians may reconsider the necessity of withholding GLP-1 RAs preoperatively based on these findings.

Patients using GLP-1 receptor agonists are more likely to be female and diagnosed with both obesity and diabetes compared to nonusers.

Understanding the demographics of GLP-1 RA users can inform targeted interventions and education.

Endoscopic hydrothermal duodenal mucosal resurfacing is well tolerated in human subjects.

Practitioners can consider this procedure as a safe option for patients.

Endoscopic hydrothermal duodenal mucosal resurfacing has an acceptable safety profile.

This procedure can be considered for patients with a focus on safety.

Testosterone replacement therapy (TR) did not increase aggression in adult male patients with Prader-Willi syndrome.

TR may be safely administered without concerns for increased aggression in this population.

Use of GLP-1 receptor agonists (GLP-1 RAs) is associated with an increased incidence of diabetic retinopathy (DR) with a hazard ratio (HR) of 1.07 (95% CI, 1.03-1.11).

Clinicians should be aware of the increased risk of DR when prescribing GLP-1 RAs to patients with T2D.

GLP-1 RAs are not associated with progression to proliferative diabetic retinopathy (HR, 1.06; 95% CI, 0.97-1.15) or diabetic macular edema (HR, 0.98; 95% CI, 0.95-1.01) in patients with preexisting DR.

Patients with preexisting DR may not experience worsening of certain complications when treated with GLP-1 RAs.

There is a need for more research on the anabolic potential of non-animal-derived protein sources.

More research is needed to evaluate the effectiveness of non-animal protein sources for muscle health.

Trials with both smartphone and in-person components exhibited the highest racial minority enrollment.

Combining technology with in-person interactions may further improve minority enrollment in weight loss trials.